Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial

Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial

Introduction Neonatal hypoxic-ischaemic encephalopathy (HIE) is an important illness associated with death or cerebral palsy. This study aims to assess the safety and tolerability of the allogenic human multilineage-differentiating stress-enduring cell (Muse cell)-based product (CL2020) cells in new...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Akihiro Hirakawa, Masahiko Ando, Masahiro Hayakawa, Nao Matsuyama, Shinobu Shimizu, Kazuto Ueda, Toshihiko Suzuki, Sakiko Suzuki, Ryosuke Miura, Akemi Katayama, Masaaki Mizuno, Yoshiaki Sato
Materialtyp: Artikel
Språk:English
Publicerad: BMJ Publishing Group 2022-04-01
Serie:BMJ Open
Länkar:https://bmjopen.bmj.com/content/12/4/e057073.full

Liknande verk

Liknande verk